CVS Health Corporation (CVS) Fair Value & Analysis
Healthcare · US · Market cap $121B
CVS Health Corporation
CVS · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Share price +17.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $55.57 – $101.66 · fair‑value band $22.86 – $70.87 · the $101.57 price screens above the $42.51 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CVS Health Corporation (CVS) currently trades at $101.57, while our model-based Fair Value estimate is $42.51 — implying the stock looks roughly 58.1% overvalued today. We read business quality at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, CVS Health Corporation generated revenue of $406B at a net margin of 0.7%. Revenue grew 6.1% year over year. It earns a return on equity of 3.8%. Net debt stands at $85.1B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CVS Health Corporation reported revenue of $402B in FY2025 versus $292B in FY2021, a compound +8.3%/yr. Reported net income was $1.8B in FY2025, compounding −31.4%/yr from FY2021.
Is CVS fairly valued? → Check now
Recent news
- Health Insurance Providers Stocks Q1 Recap: Benchmarking Oscar Health (NYSE:OSCR)
- CVS Health Corporation (CVS) Hits Fresh High: Is There Still Room to Run?
- How CVS Health Is Helping America Celebrate Its 250th Anniversary
- 2 Healthcare Stocks with Competitive Advantages and 1 Facing Challenges
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| UNH UNH | 7,169 MXN | 5,217 MXN | -27% |
| UnitedHealth Group UNHH34 | R$29.48 | R$22.15 | -25% |
| Elevance Health, Inc E1LV34 | R$421.98 | R$83.34 | -80% |
| The Cigna Group CI | $280.68 | $500.99 | +78% |
| Humana Inc HUM | $360.72 | $112.13 | -69% |
| Molina Healthcare, Inc MOH | $197.89 | $120.63 | -39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CVS Health Corporation (CVS) undervalued?
What is the fair value of CVS?
What is the quality score of CVS?
What is the revenue of CVS Health Corporation (CVS)?
What is the net profit margin of CVS?
Does CVS Health Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.